The stock of Delcath Systems, Inc. (NASDAQ:DCTH) hit a new 52-week low and has $2.06 target or 11.00% below today’s $2.32 share price. The 6 months bearish chart indicates high risk for the $4.20 million company. The 1-year low was reported on Oct, 17 by Barchart.com. If the $2.06 price target is reached, the company will be worth $462,000 less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 22,159 shares traded hands. Delcath Systems, Inc. (NASDAQ:DCTH) has declined 58.39% since March 14, 2016 and is downtrending. It has underperformed by 64.00% the S&P500.
Analysts await Delcath Systems, Inc. (NASDAQ:DCTH) to report earnings on November, 8.
According to Zacks Investment Research, “Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.”
Insitutional Activity: The institutional sentiment decreased to 1.13 in 2016 Q2. Its down 0.30, from 1.43 in 2016Q1. The ratio dived, as 7 funds sold all Delcath Systems, Inc. shares owned while 1 reduced positions. 2 funds bought stakes while 7 increased positions. They now own 1.85 million shares or 18.13% less from 2.26 million shares in 2016Q1.
Barclays Public Limited has invested 0% of its portfolio in Delcath Systems, Inc. (NASDAQ:DCTH). Private Advisor Grp Llc last reported 0% of its portfolio in the stock. The Ontario – Canada-based Royal Comml Bank Of Canada has invested 0% in Delcath Systems, Inc. (NASDAQ:DCTH). Geode Llc accumulated 39,792 shares or 0% of the stock. Wells Fargo & Mn has 0% invested in the company for 157 shares. Ladenburg Thalmann Finance Service has invested 0% of its portfolio in Delcath Systems, Inc. (NASDAQ:DCTH). Vanguard Grp Incorporated Incorporated accumulated 0% or 77,988 shares. Kcg accumulated 12,403 shares or 0% of the stock. Deutsche Bank & Trust Ag last reported 5 shares in the company. Citadel Advsrs Lc has invested 0% of its portfolio in Delcath Systems, Inc. (NASDAQ:DCTH). Blackrock Institutional Na holds 0% or 531,871 shares in its portfolio. Creative Planning, a Kansas-based fund reported 307 shares. National Bank & Trust Of America Corporation De reported 4,604 shares or 0% of all its holdings. Renaissance Technology Limited Company last reported 0% of its portfolio in the stock. The Pennsylvania-based Susquehanna Group Incorporated Ltd Liability Partnership has invested 0% in Delcath Systems, Inc. (NASDAQ:DCTH).
More notable recent Delcath Systems, Inc. (NASDAQ:DCTH) news were published by: Marketwatch.com which released: “Delcath Systems Inc.” on December 22, 2009, also Prnewswire.com with their article: “Delcath Sponsors Ocular Melanoma Foundation Patient Retreat” published on September 19, 2016, Prnewswire.com published: “Delcath To Present At The 2016 Aegis Growth Conference” on September 12, 2016. More interesting news about Delcath Systems, Inc. (NASDAQ:DCTH) were released by: Prnewswire.com and their article: “European Data Supporting Survival Benefit With Delcath’s CHEMOSAT System …” published on July 06, 2016 as well as Globenewswire.com‘s news article titled: “Pomerantz Law Firm Has Filed a Class Action Against Delcath Systems, Inc. and …” with publication date: May 08, 2013.
DCTH Company Profile
Delcath Systems, Inc., incorporated on August 5, 1988, is a late-stage clinical development firm with early commercial activity in Europe focused on cancers of the liver. The Firm is a specialty pharmaceutical and medical device firm developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.